State of Wisconsin Investment Board acquired a new stake in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 20,000 shares of the biotechnology company’s stock, valued at approximately $115,000. State of Wisconsin Investment Board owned 0.08% of Conatus Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Rhumbline Advisers purchased a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $156,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $1,041,000. Eagle Global Advisors LLC purchased a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $156,000. Strs Ohio purchased a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $153,000. Finally, Acadian Asset Management LLC increased its position in shares of Conatus Pharmaceuticals by 641.1% in the second quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock valued at $6,324,000 after acquiring an additional 949,785 shares during the period. Hedge funds and other institutional investors own 33.13% of the company’s stock.

A number of equities analysts have issued reports on CNAT shares. Stifel Nicolaus restated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Finally, ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 24th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $13.39.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) opened at 5.94 on Friday. The company’s 50 day moving average is $5.42 and its 200 day moving average is $5.72. The stock’s market cap is $178.22 million. Conatus Pharmaceuticals Inc. has a 12 month low of $1.45 and a 12 month high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.33 million. During the same period last year, the firm earned ($0.30) EPS. On average, analysts anticipate that Conatus Pharmaceuticals Inc. will post ($0.45) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “State of Wisconsin Investment Board Takes $115,000 Position in Conatus Pharmaceuticals Inc. (CNAT)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/state-of-wisconsin-investment-board-takes-115000-position-in-conatus-pharmaceuticals-inc-cnat/1567820.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.